BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript

BioMarin Pharmaceutical (BMRN)

Q1 2012 Earnings Call

April 26, 2012 5:00 pm ET


Eugenia Shen -

Jean-Jacques Bienaimé - Chief Executive Officer and Director

Jeffrey H. Cooper - Chief Financial Officer and Senior Vice President

Henry J. Fuchs - Chief Medical Officer and Executive Vice President

Stephen Aselage - Chief Business Officer and Executive Vice President


Bryan Huang

Cory William Kasimov - JP Morgan Chase & Co, Research Division

Navdeep Singh - Deutsche Bank AG, Research Division

Salveen J. Richter - Canaccord Genuity, Research Division

Christopher J. Raymond - Robert W. Baird & Co. Incorporated, Research Division

Joseph P. Schwartz - Leerink Swann LLC, Research Division

Tim Lugo - William Blair & Company L.L.C., Research Division

Charmaine Chan - RBC Capital Markets, LLC, Research Division

Matthew Harrison - UBS Investment Bank, Research Division

Nicholas Bishop

Liana Moussatos - Wedbush Securities Inc., Research Division



A very good day to you, ladies and gentlemen, and welcome to your Q1 2012 BioMarin Pharmaceutical Inc. Earnings Conference Call, hosted by Eugenia Shen, Investor Relations, amongst other presenters. My name is Chris, and I'll be your conference coordinator for today. [Operator Instructions] I would just like to remind all party, this conference is being recorded for replay purposes today. Thank you. At this time, I would like to turn the call over to Eugena to start. Please go ahead.

Eugenia Shen

Thank you. On the call today is J.J. Bienaimé, BioMarin's CEO; Jeff Cooper, CFO; Hank Fuchs, Chief Medical Officer; and Steve Aselage, Chief Business Officer. This nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceuticals, including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half